Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year,” said ...
Iluzanebart is under clinical development by Vigil Neuroscience and currently in Phase I for Unspecified Neurologic Disorders.
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines ...
Tonix Pharmaceuticals (NASDAQ: TNXP) , a biopharmaceutical company focused on marketed products and development candidates, announced its participat ...
CHATHAM, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of ...
Series Novel Combinations (Dopamine Pathway) is under clinical development by Alto Neuroscience and currently in Phase I for Unspecified Psychiatric Disorders.
At CES 2025, Earable Neuroscience introduces FRENZ Brainband's Brainwaves Research platform for pharmas and universities collaborations. Kieu My Doan Earable Inc +1 310-686-8168 email us here Visit us ...
The stock market saw something incredible in 2024, with the “Magnificent 7” tech giants leading the charge and driving a huge ...
Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback